Central venulitis in the allograft liver a clinicopathologic study

Transplantation

Volumn 64, Issue 2, 1997, Pages 252-257

  Tsamandas, Athanassios C ^a   Jain, Ashok B ^a   Felekouras, Evangelos S ^a   Fung, John J ^a   Demetris, Anthony J ^a   Lee, Randall G ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ALLOGRAFT; ARTICLE; CENTRAL VEIN; CLINICAL ARTICLE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER BIOPSY; LIVER TOXICITY; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HEPATIC VEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VASCULITIS; VENULES;

EID: 0030761465     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707270-00013     Document Type: Article

References (14)

1. Porter KA. Pathology of the orthotopic homograft and heterograft. In: Starzl TE, Putnam CW, eds. Experience in hepatic transplantation. Philadelphia: W.B. Saunders, 1969: 422.
2. Demetris AJ, Qian S, Sun H, et al. Early events in liver allograft rejection: delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol 1991; 138: 609.
3. Demetris AJ, Fung JJ, Todo S, et al. Pathologic observation in human allograft recipients treated with FK 506. Transplant Proc 1990; 22: 25.
4. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK 506 immunosuppressive therapy: a clinicopathologic study of 96 patients. Transplantation 1992; 53: 1056.
5. Hytiroglou P, Lee R, Sharma K, et al. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients: histologic and immunopathologic observations Transplantation 1993; 56: 1389.
6. Fisher A, Mor E, Hytiroglou P, et al. FK506 hepatotoxicity in liver allograft recipients. Transplantation 1995; 59: 1631.
7. International Working Party. Terminology for hepatic allograft rejection. Hepatology 1995; 22: 648.
8. Fung J, Eliasziw M, Todo S, et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117.
9. Ludwig J, Gross JB Jr, Perkins JD, Moore SB. Persistent centrilobular necroses in hepatic allografts. Hum Pathol 1990; 21: 656.
10. Dhillon AP, Burroughs AK, Hudson M, Shah N, Rolles K, Scheuer PJ. Hepatic venular stenosis after orthotopic liver transplantation. Hepatology 1994; 19: 106.
11. Gómez R, Colina F, Moreno E, et al. Etiopathogenesis and prognosis of centrilobular necrosis in hepatic grafts. J Hepatol 1994; 21: 441.
12. Turlin B, Slapka SI, Hayllar KM, Heaton N, Williams R, Portmann B. Centrilobular necrosis after orthotopic liver transplantation: a longitudinal clinicopathologic study in 71 patients. Liver Transplant Surg 1995; 1: 285.
13. Farrell G. Diagnosis of drug-induced liver disease. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994; 153.
14. Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14: 806.